Sakar Healthcare Limited (NSE:SAKAR)
India
· Delayed Price · Currency is INR | Market Cap | 14.51B |
| Revenue (ttm) | 2.31B |
| Net Income (ttm) | 252.21M |
| Shares Out | 22.25M |
| EPS (ttm) | 11.37 |
| PE Ratio | 57.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,520 |
| Average Volume | 89,431 |
| Open | 655.90 |
| Previous Close | 652.10 |
| Day's Range | 616.35 - 661.95 |
| 52-Week Range | 264.25 - 659.85 |
| Beta | 0.11 |
| RSI | 62.19 |
| Earnings Date | May 20, 2026 |
About Sakar Healthcare
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaestheti... [Read more]
Financial Performance
In fiscal year 2025, Sakar Healthcare's revenue was 1.78 billion, an increase of 15.53% compared to the previous year's 1.54 billion. Earnings were 175.02 million, an increase of 49.96%.
Financial StatementsNews
Sakar Healthcare Ltd (NSE:SAKAR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth ...
Sakar Healthcare Ltd (NSE:SAKAR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic Oncology Advances
Q3 2026 Sakar Healthcare Ltd Earnings Call Transcript
Q3 2026 Sakar Healthcare Ltd Earnings Call Transcript
Sakar Healthcare gets EMA approval to manufacture Imatinib for Accord’s European market
Sakar Healthcare Limited has achieved a key regulatory milestone after its oncology manufacturing facility in Gujarat was approved by the...
Sakar Healthcare shares rise over 2.5% after securing nine new oncology product approvals across global markets
Friday, November 7: Shares of Sakar Healthcare Ltd gained 2.54% to Rs 400 in Friday’s session after the company announced...
Sakar Healthcare receives nine new marketing authorisations for Oncology products in EU and emerging markets
Sakar Healthcare Ltd has announced that it has received nine new Marketing Authorisations (MAs) for its oncology portfolio across the...